tradingkey.logo

Translational Development Acquisition Corp

TDACU
10.700USD
0.000
Close 11/26, 16:00ETQuotes delayed by 15 min
0.00Market Cap
0.00P/E TTM

Translational Development Acquisition Corp

10.700
0.000

More Details of Translational Development Acquisition Corp Company

Translational Development Acquisition Corp. is a blank check company. The Company is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The Company has not selected any specific business combination target, and has not engaged in any substantive discussions, directly or indirectly, with any business combination target. The Company may pursue an acquisition opportunity in any business, industry, sector or geographical location. The Company intends to focus on industries that complement its management team’s background, and to capitalize on the ability of its management team to identify and acquire a business. The Company has neither engaged in any operations nor generated any revenues.

Translational Development Acquisition Corp Info

Ticker SymbolTDACU
Company nameTranslational Development Acquisition Corp
IPO dateDec 23, 2024
CEOMr. Michael B. Hoffman
Number of employees- -
Security typeUnit
Fiscal year-end- -
Address52 E 83Rd St.
CityNEW YORK
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code10028
Phone14132042769
Website
Ticker SymbolTDACU
IPO dateDec 23, 2024
CEOMr. Michael B. Hoffman

Company Executives of Translational Development Acquisition Corp

Name
Name/Position
Position
Shareholding
Change
Mr. Avanindra C. Das
Mr. Avanindra C. Das
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Christopher Jarratt
Mr. Christopher Jarratt
Independent Director
Independent Director
--
--
Dr. Curtis T. Keith, Ph.D.
Dr. Curtis T. Keith, Ph.D.
Independent Director
Independent Director
--
--
Mr. Matthew A. Kestenbaum
Mr. Matthew A. Kestenbaum
Independent Director
Independent Director
--
--
Dr. E. Premkumar Reddy, Ph.D.
Dr. E. Premkumar Reddy, Ph.D.
Independent Director
Independent Director
--
--
Mr. Michael B. Hoffman
Mr. Michael B. Hoffman
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Avanindra C. Das
Mr. Avanindra C. Das
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Christopher Jarratt
Mr. Christopher Jarratt
Independent Director
Independent Director
--
--
Dr. Curtis T. Keith, Ph.D.
Dr. Curtis T. Keith, Ph.D.
Independent Director
Independent Director
--
--
Mr. Matthew A. Kestenbaum
Mr. Matthew A. Kestenbaum
Independent Director
Independent Director
--
--
Dr. E. Premkumar Reddy, Ph.D.
Dr. E. Premkumar Reddy, Ph.D.
Independent Director
Independent Director
--
--
Mr. Michael B. Hoffman
Mr. Michael B. Hoffman
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--

Revenue Breakdown

Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.

Shareholding Stats

Updated: Wed, Nov 12
Updated: Wed, Nov 12
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Calamos Advisors LLC
2.17%
D. E. Shaw & Co., L.P.
2.03%
Schechter Investments
0.87%
RiverNorth Capital Management LLC
0.58%
Yakira Capital Management, Inc.
0.35%
Other
94.00%
Shareholders
Shareholders
Proportion
Calamos Advisors LLC
2.17%
D. E. Shaw & Co., L.P.
2.03%
Schechter Investments
0.87%
RiverNorth Capital Management LLC
0.58%
Yakira Capital Management, Inc.
0.35%
Other
94.00%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
2.78%
Hedge Fund
2.03%
Investment Advisor
1.27%
Research Firm
0.09%
Other
93.83%

Institutional Shareholding

Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
47
2.55M
14.76%
-12.35M
2025Q2
46
4.08M
23.66%
-10.95M
2025Q1
45
4.60M
26.65%
-10.31M
2024Q4
41
14.94M
86.63%
+14.94M

Shareholder Activity

Name
Shares Held
Proportion
Change
Chg %
Date
Calamos Advisors LLC
375.00K
2.17%
--
--
Jun 30, 2025
D. E. Shaw & Co., L.P.
350.00K
2.03%
--
--
Jun 30, 2025
Schechter Investments
150.64K
0.87%
--
--
Mar 31, 2025
RiverNorth Capital Management LLC
500.00K
2.9%
--
--
Jun 30, 2025
Yakira Capital Management, Inc.
60.00K
0.35%
--
--
Jun 30, 2025
Flow Traders U.S. LLC
14.23K
0.08%
+3.85K
+37.15%
Jun 30, 2025
UBS Financial Services, Inc.
8.33K
0.05%
--
--
Jun 30, 2025
AQR Arbitrage, LLC
3.95K
0.02%
+3.95K
--
Dec 31, 2024
View more

Related ETFs

Updated: Thu, Nov 6
Updated: Thu, Nov 6
Name
Proportion
SPAC and New Issue ETF
0%
SPAC and New Issue ETF
Proportion0%

Dividend

A total of 0.00 USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data

Stock Split

Date
Type
Ratio
No Data
Date
Type
Ratio
No Data

FAQs

Who are the top five shareholders of Translational Development Acquisition Corp?

The top five shareholders of Translational Development Acquisition Corp are:
Calamos Advisors LLC holds 375.00K shares, accounting for 2.17% of the total shares.
D. E. Shaw & Co., L.P. holds 350.00K shares, accounting for 2.03% of the total shares.
Schechter Investments holds 150.64K shares, accounting for 0.87% of the total shares.
RiverNorth Capital Management LLC holds 500.00K shares, accounting for 2.90% of the total shares.
Yakira Capital Management, Inc. holds 60.00K shares, accounting for 0.35% of the total shares.

What are the top three shareholder types of Translational Development Acquisition Corp?

The top three shareholder types of Translational Development Acquisition Corp are:
Calamos Advisors LLC
D. E. Shaw & Co., L.P.
Schechter Investments

How many institutions hold shares of Translational Development Acquisition Corp (TDACU)?

As of 2025Q3, 47 institutions hold shares of Translational Development Acquisition Corp, with a combined market value of approximately 2.55M, accounting for 14.76% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -8.90%.

What is the biggest source of revenue for Translational Development Acquisition Corp?

In --, the -- business generated the highest revenue for Translational Development Acquisition Corp, amounting to -- and accounting for --% of total revenue.
KeyAI